Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Trading Update

18 Jan 2005 07:00

Embargoed Release: 07:00hrs Tuesday 18 January 2005 SOPHEON PLC (`Sopheon' or `the Company') TRADING UPDATE Sopheon plc, the international provider of solutions that improve the returnfrom innovation and product development, announces that the Company's EBITDAresult for the final quarter of 2004 is expected to be positive, and that theconsolidated annual EBITDA loss for 2004 is expected to be in line with brokerforecasts of ‚£1.15m (2003 - ‚£4.07m). Sales growth over the prior year achievedin Sopheon's continuing software business is substantial, however, totalreported revenues for 2004 are expected to be moderately below brokerforecasts. This expectation is due in part to the weakness in the dollar duringthe later stages of the year. Nevertheless the overall effect of the weakdollar is expected to have been marginally positive, due to the fact that alarge portion of Sopheon's costs are dollar denominated.As indicated in earlier announcements, the final quarter performance wasdependent on completion of major sales in December. Sopheon was successful insigning three such orders. Each customer is a global leader in its respectiveindustry and a widely recognized name, and two of the transactions includedlicense fees of around $600,000. Apart from their financial and brand value,these deals underpin Sopheon's credentials in two industries with significantidentified potential: fast-moving consumer goods (FMCG) and financial services.Several other transactions were concluded during the quarter, primarily in thechemicals sector, where we already have a substantial base of customers. Wecontinue to focus on pipeline creation and extending business with existingcustomers. An excellent example of the latter is BASF. Developed as a customerthrough one of Sopheon's distribution partners, BASF began implementation ofAccolade a year ago. Our relationship with this chemicals industry leader hasgrown rapidly since then, and BASF is now one of four Sopheon clients that havecontracted for 2000 or more Accolade seat-licenses.Sopheon made important progress in 2004 in positioning itself for the longerterm by securing partnerships on two fronts: strategic alliances in keymarkets, and distribution partners in geographical areas outside the Company'sexisting sphere of operations. As a result of this effort we are part ofMicrosoft's Collaborative Product Development initiative. Since announcement ofthe program in October, Microsoft and Sopheon have been working together toenhance and promote the integration of their technologies. To enabledevelopment efforts arising from this and other initiatives, and with supportfrom Microsoft, Sopheon implemented a controlled expansion in R&D resources,recruiting into our Denver development center. During the year Sopheon alsoundertook a successful balance sheet restructuring, and continues to haveaccess to the group's ¢â€š¬10m equity line, of which over 90% remains untapped.Financial expectations noted above are subject to the completion of theyear-end financial close process. Consistent with prior years, Sopheon plans toissue its 2004 preliminary results around the end of March.Sopheon's Chairman, Barry Mence said:"Achieving a positive quarterly result is an important milestone for Sopheon.We are focused on the challenge of maintaining this momentum into the firsthalf of 2005, encouraged by our recent successes and the opportunities that arebuilding through our strategic relationships."For further information contact:Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO Adam Reynolds Hansard Communications Tel : + 44 (0) 207 245 1100 Andrew Tan + 44 (0) 7957 203 685 Barbara Jansen Citigate First Financial Tel : + 31 (0) 205 754 010About SopheonSopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product development. TheSopheon Accolade‚® product development system automates gate- or phase-basedproduct development (PD) processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time to market. Sopheon is listed on the AIM market of the LondonStock Exchange and on the Euronext in the Netherlands. For more information,please visit www.sopheon.com.END
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.